At 2 years , differences in the primary end point of cardiac death , target-vessel myocardial infarction , and target lesion revascularization continued to diverge in favor of BES-treated patients ( 5.8 % ) compared with BMS-treated patients ( 11.9 % ; hazard ratio = 0.48 ; 95 % confidence interval , 0.31-0 .72 ; P < 0.001 ) with a significant risk reduction during the second year of follow-up ( hazard ratio 1-2 years = 0.45 ; 95 % confidence interval , 0.20-1 .00 ; P = 0.049 ) .